Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPN-59011
- Development stage
- Phase 1
- Lead developer
- Ipsen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
IPN-59011 is a novel neurotoxin developed by Ipsen for the treatment of moderate to severe upper facial lines (facial wrinkles). It acts as an antagonist of the acetylcholine receptor (AChR), specifically targeting the nAChR alpha1, beta1, delta, and gamma subunits. The drug was designed to have a longer duration of action compared to currently marketed products for facial wrinkle reduction. Its development reached up to Phase 2 clinical trials but has since been discontinued[1][2][7].
02
Targets
Muscle-type nicotinic acetylcholine receptorCHRNA1 (nAChR α1 subunit)CHRNB1 (nAChR beta-1 subunit)CHRND (nAChR delta subunit)CHRNG (nAChR gamma subunit)
Beyond the preview
Go deeper on IPN-59011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPN-59011.